关于先锋

Company Profile

Company profile

R & D innovation

Cooperation profile

Anhui Pioneer Pharmaceutical Co., Ltd

Anhui Pioneer Pharmaceutical Co., Ltd. is a comprehensive national high-tech enterprise integrating production, sales and scientific research. It was established in January 2004 with a registered capital of 20 million yuan. It is located in the center of the high-tech zone and covers an area of more than 30 mu. The construction area is 30000㎡. The company has domestic advanced freeze-dried powder injections, cephalosporin powder injections, capsules, tablets, granules, external solutions, traditional Chinese medicine extraction and other production lines. The products cover cardiovascular, respiratory, antibacterial and anti-inflammatory and other therapeutic fields.

2004

Founded in 2004

2000

Registered capital

30000

Construction area

300

Has more than 300 employees

38

38 full-time R&D personnel

8

8 licensed pharmacists

The company has more than 300 employees, 40% of whom have a bachelor’s degree or above; there are 38 full-time R&D personnel in the technology center, and 8 licensed pharmacists; since its establishment, the company has paid a total of nearly 300 million yuan in taxes. The company has the courage to undertake social responsibilities and solve local employment problems and make a greater contribution to local taxation.

The company has passed a number of honorary certifications

National high-tech enterprise

Hefei city average contribution class A enterprise

Specialized, Specialized and New SMEs in Anhui Province

Gazelle Enterprise in High-tech Zone

Anhui Enterprise Technology Center

Hefei Engineering Research Center

Growth Subsidy for High-tech Enterprises in Anhui Province

Growth Subsidy for Three High-tech Enterprises in Hefei

Hefei High-tech Zone Triple-Creation Subsidy

Hefei Enterprise Technology Center

Deep technology enterprise

Wanmei Brand Enterprise in Anhui Province

Pioneer and universities carry out various forms of research and development cooperation

In 2015, the company established a modern research institute Shanghai Haofeng Pharmaceutical Technology Co., Ltd. in Shanghai Zhangjiang Hi-Tech, relying on the geographical and resource advantages of Zhangjiang National Development Zone, continuously injecting new vitality into the company. The company integrates the resources of Shanghai Haofeng R&D Base and Hefei Headquarters R&D Center, establishes the Anhui Provincial Enterprise Technology Center, and builds a relatively complete technological innovation system with the enterprise as the main body, combining production, learning, research and use, and Anhui Traditional Chinese Medicine University, Shanghai Jiaotong University, Anhui Agricultural University and other universities carry out various forms of research and development cooperation.

Anhui Pioneer Pharmaceutical Co., Ltd
Anhui Pioneer Pharmaceutical Co., Ltd
30 The market covers nearly 30 provinces across the country

Under the general environment of the structural adjustment of the national pharmaceutical market, our company has continuously strengthened its research and development capabilities, innovated marketing models, explored the market and opened up new channels, and the company has entered a benign development track. The company's products have also established a good market reputation. The company's leading products, clindamycin hydrochloride for injection, clindamycin phosphate for injection, Guipi capsules and diammonium glycyrrhizinate enteric-coated tablets, have been recognized by the market, and the market covers nearly 30 provinces. Among them, Haorui® Clindamycin Hydrochloride for Injection and Baisining® Guipi Capsules have ranked first in the market share of similar products for five consecutive years since 2018.

In 2023, Anhui Pioneer Pharmaceutical officially launched the listing plan. It is planned that the company will be listed on the Beijing Stock Exchange and the Growth Enterprise Market in 2026. After the end of the company's first five-year plan, it will usher in a bright future where the company will spread its wings and rejuvenate!

公司简介

安徽省先锋制药有限公司是一家集生产、销售、科研于一体的综合型国家高新技术企业，企业成立于2004年1月，注册资本2000万元，位于高新区的中心地带，占地30余亩，建筑面积30000㎡。企业建有国内先进的冻干粉针剂、头孢粉针剂、胶囊剂、片剂、颗粒剂、外用溶液剂、中药提取等多条生产线，产品覆盖心血管、呼吸、抗菌消炎等多个治疗领域。

公司拥有职工300余人，本科及以上学历占比达40%；技术中心专职研发人员38人，执业药师8人；企业自成立以来，累计纳税近3亿元，企业勇于承担社会责任，解决本地就业问题，为本地税收做出较大贡献。公司先后通过“国家级高新技术企业”、“合肥市亩均贡献A类企业”、“安徽省专精特新中小企业”、“高新区瞪羚企业”、“安徽省企业技术中心”“合肥市工程研究中心（合肥市新盐型药物工程研究中心）”、“安徽省三重一创高新技术企业增长补助”、“合肥市三重一创高新技术企业增长补助”、“合肥高新区三重一创补助”、“合肥市企业技术中心”、“深科技企业”、“安徽省皖美品牌企业”等荣誉认证。

2015年公司在上海张江高科建立了现代化的研究所上海皓锋医药科技有限公司，依托张江国家开发区的地域及资源优势，为公司源源不断的注入新的活力。公司整合上海皓锋研发基地和合肥总部研发中心资源，建立了安徽省企业技术中心，构建了较为完善的以企业为主体，产、学、研、用相结合的技术创新体系，与安徽中医药大学、上海交通大学、安徽省农业大学等高校开展多种形式研发合作。

在全国医药市场结构调整的大环境下，我公司不断加强研发力量、创新营销模式、探索市场开拓新渠道，公司进入了一种良性的发展轨道。公司产品也建立了良好市场口碑，公司主导产品注射用盐酸克林霉素、注射用克林霉素磷酸酯、归脾胶囊和甘草酸二铵肠溶片等被市场所认可，市场覆盖全国近30个省份。其中皓瑞®注射用盐酸克林霉素、百思宁®归脾胶囊自2018年以来，连续5年占同类产品市场份额排名第一。

2023年安徽省先锋制药正式启动上市计划，计划2026年企业在北交所和创业板上市挂牌，企业第一个五年计划结束后，将迎来企业展翅腾飞、焕发新生的美好未来！